title: Changes of hypertonic saline-induced masseter muscle pain characteristics, by an infusion of the serotonin receptor type 3 antagonist granisetron.
abstract: This study aimed to investigate whether granisetron reduces masseter muscle pain and allodynia induced by hypertonic saline. Fifteen healthy women and 15 age-matched healthy men participated in this randomized, placebo-controlled, double-blinded study. They first received bilateral injections of hypertonic saline into the masseter muscles (internal control). The evoked pain intensity and the pressure-pain threshold (PPT) were recorded during 30 minutes. Granisetron was then injected on one side and placebo (normal saline) on the contralateral side. Two minutes thereafter, the hypertonic saline injections were repeated. Pain and PPT were again recorded. The first injection of hypertonic saline induced pain of similar intensity, duration, and pain area on both sides, but with larger pain area in the women (P = .017). The PPT did not change significantly. The second injection of hypertonic saline induced considerably less pain (62.5%), of shorter duration (44.1%), and of smaller area (77.4%) on the side pretreated with granisetron (P = .005). The PPT was increased on the granisetron side in the men (P = .002). The results of this study show that local injection of a single dose of granisetron attenuates masseter muscle pain induced by hypertonic saline.
  
  
  CONCLUSIONS
  This article presents the changes of hypertonic saline-induced masseter muscle pain characteristics by infusion of granisetron. It appears that the pain-inducing effect in this experimental pain model is partly due to activation of 5-HT3-receptors. Hence, the results indicate that granisetron might offer a new treatment approach for localized myofascial pain.
authors.affiliation: Department of Clinical Oral Physiology, Institute of Odontology, Karolinska Institutet, Huddinge, Sweden. nikolaos.christidis@ki.se
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Christidis
authors.forename: Kiriaki
authors.initials: K
authors.lastname: Ioannidou
authors.forename: Milena
authors.initials: M
authors.lastname: Milosevic
authors.forename: Märta
authors.initials: M
authors.lastname: Segerdahl
authors.forename: Malin
authors.initials: M
authors.lastname: Ernberg
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005157:Facial Pain / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D017829:Granisetron / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008406:Masseter Muscle / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000009:adverse effects; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017829:Granisetron; D012462:Saline Solution, Hypertonic; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists